Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

18%

2 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(33.3%)

N/A

3(33.3%)

Phase 4

1(11.1%)

Phase 3

1(11.1%)

Phase 2

1(11.1%)

9Total

Phase 1(3)

N/A(3)

Phase 4(1)

Phase 3(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT03726892Not ApplicableUnknown

Comparison of MECHANISM of Early and Late Vascular Responses Following Treatment of ST-elevation Acute Myocardial Infarction With Two Different Everolimus-eluting Stents: Randomized Controlled Trial Between Biodegradable Polymer and Durable Polymer Stent (MECHANISM-AMI-RCT)

Role: lead

NCT02014753Completed

Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting Cobalt-CHromium Stent and Platelet AggregatioN studIeS for TreatMent of Acute Myocardial InfarctionTreatment of ST-elevation Acute Myocardial Infarction

Role: lead

NCT03843567Not ApplicableUnknown

Prediction of Diminutive/Small Polyp Histology: Didactic vs. Computer-based Training

Role: collaborator

NCT01712802Not ApplicableCompleted

Multicenter Study of Denture Adhesive

Role: collaborator

NCT01905969Unknown

Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy

Role: lead

NCT00633204Phase 2Unknown

Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer